All Stories

  1. Evolutionary Perspective of Nonclassical MHC Class I and Innate-like T Cells Relevance in Immune Surveillance
  2. The future of comparative immunology viewed from the perspective of Xenopus research
  3. Ingestion of polyethylene terephthalate microplastic water contaminants by Xenopus laevis tadpoles negatively affects their resistance to ranavirus infection and antiviral immunity
  4. Exploring the Role of a Putative Secondary Metabolite Biosynthesis Pathway in Mycobacterium abscessus Pathogenesis Using a Xenopus laevis Tadpole Model
  5. The Binding, Infection, and Promoted Growth of Batrachochytrium dendrobatidis by the Ranavirus FV3
  6. Larval T Cells Are Functionally Distinct from Adult T Cells in Xenopus laevis
  7. Raising concerns on questionable ethics approvals – a case study of 456 trials from the Institut Hospitalo-Universitaire Méditerranée Infection
  8. Introduction to the special issue Amphibian immunity: stress, disease and ecoimmunology
  9. The amphibian immune system
  10. Environmental endocrine disruptors and amphibian immunity: A bridge between the thyroid hormone axis and T cell development
  11. Amphibians as a model to study the role of immune cell heterogeneity in host and mycobacterial interactions
  12. Evolution and Potential Subfunctionalization of Duplicated fms-Related Class III Receptor Tyrosine Kinase flt3s and Their Ligands in the Allotetraploid Xenopus laevis
  13. γδ T, NKT, and MAIT Cells During Evolution: Redundancy or Specialized Functions?
  14. Virus-Targeted Transcriptomic Analyses Implicate Ranaviral Interaction with Host Interferon Response in Frog Virus 3-Infected Frog Tissues
  15. TLR5-Mediated Reactivation of Quiescent Ranavirus FV3 in Xenopus Peritoneal Macrophages
  16. Virus-Targeted Transcriptomic Analyses Implicate Ranaviral Interaction with Host Interferon Response in Frog Virus 3-infected Frog Tissues
  17. Thyroid Disrupting Chemicals in Mixture Perturb Thymocyte Differentiation in Xenopus laevis Tadpoles
  18. Developing Tadpole Xenopus laevis as a Comparative Animal Model to Study Mycobacterium abscessus Pathogenicity
  19. Immunological Aspects of Chytridiomycosis
  20. Introduction
  21. Evolutionary Underpinnings of Innate-Like T Cell Interactions with Cancer
  22. Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus
  23. Developmental exposure to chemicals associated with unconventional oil and gas extraction alters immune homeostasis and viral immunity of the amphibian Xenopus
  24. Critical Role of an MHC Class I-Like/Innate-Like T Cell Immune Surveillance System in Host Defense against Ranavirus (Frog Virus 3) Infection
  25. Developmental Exposure to a Mixture of 23 Chemicals Associated With Unconventional Oil and Gas Operations Alters the Immune System of Mice
  26. Distinct MHC class I-like interacting invariant T cell lineage at the forefront of mycobacterial immunity uncovered in Xenopus
  27. Frog's DCs have it all in one
  28. RNAi-Mediated Loss of Function of Xenopus Immune Genes by Transgenesis
  29. An Ancestral Immune Surveillance System in the Amphibian Xenopus Connecting Certain Heat Shock Proteins with Classical and Nonclassical MHC Class I Molecules
  30. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours
  31. Xenopus-FV3 host-pathogen interactions and immune evasion
  32. Collagen-Embedded Tumor Transplantations in Xenopus laevis Tadpoles
  33. Exploring the functions of nonclassical MHC class Ib genes in Xenopus laevis by the CRISPR/Cas9 system
  34. Long term effects of carbaryl exposure on antiviral immune responses in Xenopus laevis
  35. Clinical impact of extensive molecular profiling in advanced cancer patients
  36. Evolutionary Aspects of Macrophages Polarization
  37. Evolutionary Perspective of Tumorigenesis and Antitumor Immunity: A Comparative Approach
  38. Genome evolution in the allotetraploid frog Xenopus laevis
  39. Recombinant Ranaviruses for Studying Evolution of Host–Pathogen Interactions in Ectothermic Vertebrates
  40. Evolution of innate-like T cells and their selection by MHC class I-like molecules
  41. Amphibian macrophage development and antiviral defenses
  42. Preface to the special issue “Hematopoiesis and immunity”
  43. Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients
  44. Frog Virus 3 dissemination in the brain of tadpoles, but not in adult Xenopus, involves blood brain barrier dysfunction
  45. Ouro proteins are not essential to tail regression during Xenopus tropicalis metamorphosis
  46. A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy
  47. Xenopus tumor model
  48. Xenopus in vivo imaging of inflammation
  49. Characterization of Frog Virus 3 knockout mutants lacking putative virulence genes
  50. Retention of duplicated ITAM-containing transmembrane signaling subunits in the tetraploid amphibian species Xenopus laevis
  51. Nonclassical MHC-Restricted Invariant Vα6 T Cells Are Critical for Efficient Early Innate Antiviral Immunity in the Amphibian Xenopus laevis
  52. Distinct functional roles of amphibian (Xenopus laevis) colony-stimulating factor-1- and interleukin-34-derived macrophages
  53. Renouvellement des cellules souches et épidémiologie des cancers – À propos d’un article de Tomasetti et Vogelstein paru dans Science
  54. Xenopus laevis tadpoles anti-FV3 IFNλ response
  55. Ranavirus Host Immunity and Immune Evasion
  56. Inflammation-Mediated FV3 Reactivation
  57. Negative effects of low dose atrazine exposure on the development of effective immunity to FV3 in Xenopus laevis
  58. On the use of pharmacogenetics in cancer treatment and clinical trials
  59. Divergent antiviral roles of amphibian (Xenopus laevis) macrophages elicited by colony-stimulating factor-1 and interleukin-34
  60. Ciblage de mTOR et identification de «répondeurs exceptionnels»
  61. Evolution of nonclassical MHC-dependent invariant T cells
  62. Environmental dependency of amphibian–ranavirus genotypic interactions: evolutionary perspectives on infectious diseases
  63. A prominent role for invariant T cells in the amphibian Xenopus laevis tadpoles
  64. Differential transcription of fathead minnow immune-related genes following infection with frog virus 3, an emerging pathogen of ectothermic vertebrates
  65. A critical role of non-classical MHC in tumor immune evasion in the amphibian Xenopus model
  66. Unusual evolutionary conservation and further species-specific adaptations of a large family of nonclassical MHC class Ib genes across different degrees of genome ploidy in the amphibian subfamily Xenopodinae
  67. FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
  68. No association between XRCC3 Thr241Met and XPD Lys751Gln polymorphisms and the risk of colorectal cancer in West Algerian population: a case–control study
  69. Amphibian IFN responses to the ranavirus FV3
  70. A functionalized heterobimetallic99mTc/Re complex as a potential dual-modality imaging probe: synthesis, photophysical properties, cytotoxicity and cellular imaging investigations
  71. Mechanisms of amphibian macrophage development: characterization of the Xenopus laevis colony-stimulating factor-1 receptor
  72. Cytotoxic effect of chlorpyrifos ethyl and its degradation derivatives by Pseudomonas peli strain isolated from the Oued Hamdoun River (Tunisia)
  73. Evaluation of antiproliferative and antioxidant activities of the organic extract and its polar fractions from the Mediterranean gorgonian Eunicella singularis
  74. Xenopus Class Ib-restricted iT cells
  75. Recent Research Progress and Potential Uses of the Amphibian Xenopus as a Biomedical and Immunological Model System
  76. Antitumor activity of semisynthetic derivatives of Aconitum alkaloids
  77. Antiproliferative activity and phenolics of the Mediterranean seaweed Laurencia obusta
  78. Biologie de la métastase
  79. Decolorization does not always mean detoxification: case study of a newly isolated Pseudomonas peli for decolorization of textile wastewater
  80. Effective RNAi-mediated  2-microglobulin loss of function by transgenesis in Xenopus laevis
  81. Xenopus liver macrophage precursors
  82. Short curcumin treatment modulates oxidative stress, arginase activity, aberrant crypt foci, and TGF-β1 and HES-1 transcripts in 1,2-dimethylhydrazine-colon carcinogenesis in mice
  83. R4 regulators of G protein signaling (RGS) identify an ancient MHC-linked synteny group
  84. Susceptibility of Xenopus laevis tadpoles to infection by the ranavirus Frog-Virus 3 correlates with a reduced and delayed innate immune response in comparison with adult frogs
  85. Gene Expression Signature Predicting High-Grade Prostate Cancer Responses to Oxaliplatin
  86. Hemisynthesis and antiproliferative properties of mono-[O-(14-benzoylaconine-8-yl)]esters and bis-[O-(14-benzoylaconine-8-yl)]esters
  87. Signalisation cellulaire et cancer : caractérisation de cibles thérapeutiques
  88. Immune Evasion Strategies of Ranaviruses and Innate Immune Responses to These Emerging Pathogens
  89. Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients
  90. Anti‐Inflammatory and Antiproliferative Activities of Organic Fractions from the Mediterranean Brown Seaweed, Cystoseira Compressa
  91. Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity
  92. “Ranaviruses: An emerging threat to ectothermic vertebrates” Report of the First International Symposium on Ranaviruses, Minneapolis MN July 8, 2011
  93. 7β-Hydroxycholesterol-induced energy stress leads to sequential opposing signaling responses and to death of c6 glioblastoma cells
  94. Evaluation of antiproliferative and anti-inflammatory activities of methanol extract and its fractions from the Mediterranean sponge
  95. Optimized transgenesis in Xenopus laevis/gilli isogenetic clones for immunological studies
  96. Anti-inflammatory, anti-proliferative and anti-oxidant activities of organic extracts from the Mediterranean seaweed, Cystoseira crinita
  97. Ranavirus: past, present and future
  98. Médicaments anticancéreux : de la chimiothérapie cytotoxique aux thérapies ciblées
  99. Les inhibiteurs de tyrosine kinase
  100. Antiviral Immunity in Amphibians
  101. Waterborne infectivity of the Ranavirus frog virus 3 in Xenopus laevis
  102. The genus Xenopus as a multispecies model for evolutionary and comparative immunobiology of the 21st century
  103. Comparative Study of Skin Graft Tolerance and Rejection in the Frog Xenopus Laevis
  104. Improved Knockout Methodology Reveals That Frog Virus 3 Mutants Lacking either the 18K Immediate-Early Gene or the Truncated vIF-2  Gene Are Defective for Replication and Growth In Vivo
  105. Encapsulation of Docetaxel into PEGylated Gold Nanoparticles for Vectorization to Cancer Cells
  106. La pollution atmosphérique, cause de cancer bronchique ?
  107. Ecology of Viruses Infecting Ectothermic Vertebrates-The Impact of Ranavirus Infections on Amphibians
  108. ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
  109. Phylogenetic and developmental study of CD4, CD8 α and β T cell co-receptor homologs in two amphibian species, Xenopus tropicalis and Xenopus laevis
  110. Présentation générale des mécanismes de réparation de l'ADN
  111. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma
  112. Vers une prescription individualisée des traitements anticancéreux
  113. Remarkable Conservation of Distinct Nonclassical MHC Class I Lineages in Divergent Amphibian Species
  114. Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models
  115. Signalisation cellulaire et cancer
  116. Polymorphismes génétiques
  117. Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins
  118. Comparative in vivo Study of gp96 Adjuvanticity in the Frog Xenopus laevis
  119. Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates
  120. Phylogeny, genomic organization and expression of λ and κ immunoglobulin light chain genes in a reptile, Anolis carolinensis
  121. The Genome of the Western Clawed Frog Xenopus tropicalis
  122. Innate Immune Responses and Permissiveness to Ranavirus Infection of Peritoneal Leukocytes in the Frog Xenopus laevis
  123. The amphibians Xenopus laevis and Silurana tropicalis possess a family of activating KIR-related Immunoglobulin-like Receptors
  124. Emerging Ranaviral Infectious Diseases and Amphibian Decline
  125. Expression Profiling the Temperature-Dependent Amphibian Response to Infection by Batrachochytrium dendrobatidis
  126. Mass mortality associated with a frog virus 3- like Ranavirus infection in farmed tadpoles Rana catesbeiana from Brazil
  127. Control of asthma in children: still unacceptable? A French cross-sectional study
  128. Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model
  129. Genome-Wide Transcriptional Response of Silurana (Xenopus) tropicalis to Infection with the Deadly Chytrid Fungus
  130. ABC Transporters and Multidrug Resistance
  131. The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models
  132. Isolation of a Latimeria menadoensis heat shock protein 70 (Lmhsp70) that has all the features of an inducible gene and encodes a functional molecular chaperone
  133. Novel nonclassical MHC class Ib genes associated with CD8 T cell development and thymic tumors
  134. Current knowledge of the immune system of the amphibian Xenopus.
  135. Xenopus, a unique comparative model to explore the role of certain heat shock proteins and non-classical MHC class Ib gene products in immune surveillance
  136. Diversity of the FcR- and KIR-related genes in an amphibian Xenopus
  137. Tumorigenesis and anti-tumor immune responses in Xenopus
  138. In vivo and in vitro techniques for comparative study of antiviral T-cell responses in the amphibian Xenopus
  139. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
  140. Impact of EGFR Gene Polymorphisms on Anticancer Drug Cytotoxicity In Vitro
  141. A chemotherapy-associated senescence bystander effect in breast cancer cells
  142. Synthesis and antiproliferative activity of aryl- and heteroaryl-hydrazones derived from xanthone carbaldehydes
  143. The Xenopus FcR family demonstrates continually high diversification of paired receptors in vertebrate evolution
  144. Protein arginine (N)‐methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins
  145. Phylogenetic Conservation of Glycoprotein 96 Ability to Interact with CD91 and Facilitate Antigen Cross-Presentation
  146. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome
  147. Localization and Differential Expression of Activation-Induced Cytidine Deaminase in the Amphibian Xenopus upon Antigen Stimulation and during Early Development
  148. Les poisons du fuseau
  149. XENOPUS LAEVIS: A POSSIBLE VECTOR OF RANAVIRUS INFECTION?
  150. Conservation of IL‐6 trans‐signaling mechanisms controlling L‐selectin adhesion by fever‐range thermal stress
  151. Involvement of nonclassical MHC class Ib molecules in heat shock protein‐mediated anti‐tumor responses
  152. Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene
  153. Inhibition of Topoisomerase I Cleavage Activity by Thiol-reactive Compounds
  154. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors
  155. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel
  156. Prédiction de la réponse aux anticancéreux par analyse du transcriptome
  157. Techniques de recherche des polymorphismes génétiques
  158. In Vivo Study of T-Cell Responses to Skin Alloantigens in Xenopus Using a Novel Whole-Mount Immunohistology Method
  159. A phase II study for the evaluation of quinine as a modulator of multidrug resistance in non-Hodgkin’s lymphoma
  160. Characterization of Primary and Memory CD8 T-Cell Responses against Ranavirus (FV3) in Xenopus laevis
  161. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls
  162. Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines
  163. Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel
  164. A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours
  165. Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients
  166. Structural Phylogenetic Analysis of Activation-Induced Deaminase Function
  167. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells
  168. Experimental study of dexrazoxane–anthracycline combinations using the model of isolated perfused rat heart
  169. Generation of a long-lasting, protective, and neutralizing antibody response to the ranavirus FV3 by the frog Xenopus
  170. 8-O-Azeloyl-14-benzoylaconine: A new alkaloid from the roots of Aconitum karacolicum Rapcs and its antiproliferative activities
  171. Major improvement of the reference method of the French drug resistance network for P-glycoprotein detection in human haematological malignancies
  172. Predicting drug response and toxicity based on gene polymorphisms
  173. Pharmacog�n�tique?pharmacog�nomie, quelle est la diff�rence?
  174. Pharmacogenetics of MDR family proteins
  175. Pharmacog�n�tique de l?irinot�can: la carboxylest�rase 2
  176. Prediction of anticancer drug response by transcriptome analysis. The new pathways of pharmacogenomics
  177. Techniques de recherche des polymorphismes génétiques
  178. Adaptive immunity and histopathology in frog virus 3-infected Xenopus
  179. CD91 up-regulates upon immune stimulation in Xenopus adult but not larval peritoneal leukocytes
  180. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38
  181. Phylogenetic Conservation of gp96-Mediated Antigen-Specific Cellular Immunity: New Evidence from Adoptive Cell Transfer in Xenopus
  182. Predicting drug response based on gene expression
  183. Anti‐tumor MHC class Ia‐unrestricted CD8 T cell cytotoxicity elicited by the heat shock protein gp96
  184. Pharmacogénétique et pharmacogénomique des cancers
  185. Xenopus as an experimental model for studying evolution of hsp–immune system interactions
  186. Molecular Determinants of the Cytotoxicity of Platinum Compounds
  187. Multidrug Resistance Reversal Agents
  188. Signaling FcRγ and TCRζ subunit homologs in the amphibian Xenopus laevis
  189. Ontogeny of Xenopus NK cells in the absence of MHC class I antigens
  190. DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer
  191. Development and characterization of a model system to study amphibian immune responses to iridoviruses
  192. Evolution of heat shock protein and immunity
  193. Bacterial stimulation upregulates the surface expression of the stress protein gp96 on B cells in the frog Xenopus
  194. Identification and characterization of Xenopus CD8+ T cells expressing an NK cell-associated molecule
  195. Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan: Figure 1
  196. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines
  197. Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes
  198. Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells
  199. Minor Histocompatibility Antigen-Specific MHC-Restricted CD8 T Cell Responses Elicited by Heat Shock Proteins
  200. MHC-RESTRICTED AND -UNRESTRICTED CD8 T CELLS
  201. Metabolism of methoxymorpholino‐doxorubicin in rat, dog and monkey liver microsomes: comparison with human microsomes
  202. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants
  203. Resistance to cytotoxic agents
  204. Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver
  205. Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome
  206. In vitro thymocyte differentiation in MHC class I-negative Xenopus larvae
  207. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines
  208. Down-regulation of bcr-abl and bcl-xL expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors
  209. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia
  210. B‐cell development in the amphibian Xenopus
  211. B-cell development in the amphibian Xenopus
  212. New targets, new drugs
  213. Preclinical Evaluation of the Cardiotoxicity of Taxane–Anthracycline Combinations Using the Model of Isolated Perfused Rat Heart
  214. Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance
  215. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients
  216. Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
  217. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model
  218. Multidrug resistance in oncology: diagnostic and therapeutic approaches
  219. In vitro differentiation of a CD4/CD8 double-positive equivalent thymocyte subset in adult Xenopus
  220. Ontogeny of CTX expression in xenopus
  221. Evolution of immune surveillance and tumor immunity: studies in Xenopus
  222. Resistance to Anticancer Drugs: Are We Ready to Use Biologic Information for the Treatment of Patients With Cancer?
  223. Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy
  224. The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry
  225. Approaches to multidrug resistance reversal
  226. Doxorubicin-Induced Alterations of c-myc and c-jun Gene Expression in Rat Glioblastoma Cells: Role of c-jun in Drug Resistance and Cell Death
  227. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
  228. Determination of unbound platinum after oxaliplatin administration
  229. Drug resistance to topoisomerase II inhibitors
  230. Transcriptional down-regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine
  231. Pharmacology of irinotecan
  232. A Simple Chromatographic Method for the Analysis of Pyrimidines and their Dihydrogenated Metabolites
  233. Genealogical study of oculopharyngeal muscular dystrophy in France
  234. Antibody Cross-Linking of the Thymocyte-Specific Cell Surface Molecule CTX Causes Abnormal Mitosis and Multinucleation of Tumor Cells
  235. Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma
  236. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms
  237. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin
  238. Confocal microscopy of idarubicin localisation
  239. French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours
  240. Multicentric evaluation of the MDR phenotype in leukemia
  241. Differential Stabilization of Topoisomerase‐II–DNA Cleavable Complexes by Doxorubicin and Etoposide in Doxorubicin‐Resistant Rat Glioblastoma Cells
  242. Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance
  243. Cross-linking CTX, a novel thymocyte-specific molecule, inhibits the growth of lymphoid tumor cells in xenopus
  244. Glucuronidation of SN‐38, the Active Metabolite of Irinotecan, by Human Hepatic Microsomes
  245. Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation
  246. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver Carboxylesterase
  247. Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture
  248. Semisynthesis of RPR 121056A, a major metabolite of irinotecan (CPT-11)
  249. CTX, a novel molecule specifically expressed on the surface of cortical thymocytes inXenopus
  250. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention
  251. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance
  252. Xenopus lymphoid tumor cell lines
  253. Xenopus lymphoid tumor cell lines
  254. Ontogeny of the alloimmune response against a transplanted tumor in Xenopus laevis
  255. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line
  256. Azelastine and flezelastine as reversing agents of multidrug resistance: Pharmacological and molecular studies
  257. A Xenopus lymphoid tumor cell line with complete Ig genes rearrangements and T-cell characteristics
  258. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line
  259. Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines
  260. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin
  261. Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells
  262. Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan
  263. Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives
  264. Pharmacological Properties of Oral Idarubicin
  265. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma
  266. Intracellural accretion of free and nanosphere-encapsulated doxorubicin
  267. Clinical Pharmacokinetics of Epirubicin
  268. Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil
  269. Individual dose adaptation of anticancer drugs
  270. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance
  271. Expression of MDR1/P glycoprotein in human sarcomas
  272. Lymphoid Tumors of Xenopus laevis with Different Capacities for Growth in Larvae and Adults
  273. Differential over‐expression of mdr1 genes in multidrug‐resistant rat glioblastoma cell lines selected with doxorubicin or vincristine
  274. Doxorubicin‐induced oxygen free radical formation in sensitive and doxorubicin‐ resistant variants of rat glioblastoma cell lines
  275. Doxorubicin‐induced oxygen free radical formation in sensitive and doxorubicin‐resistant variants of rat glioblastoma cell lines
  276. Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines
  277. Doxorubicin‐induced oxygen free radical formation in sensitive and doxorubicin‐resistant variants of rat glioblastoma cell lines
  278. Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines
  279. Clinical Pharmacokinetics of Idarubicin
  280. Diffusion of a particular 4.1(−) hereditary elliptocytosis allele in the French northern Alps
  281. Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-hodgkin's lymphoma
  282. Doxorubicin‐induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin
  283. Epirubicin
  284. New drug design and development in cancer: present status and future perspectives
  285. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells
  286. Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines
  287. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
  288. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines
  289. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients
  290. Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities
  291. Measurement of doxorubicin-induced lipid peroxidation under the conditions that determine cytotoxicity in cultured tumor cells
  292. Drug resistance in oncology: from concepts to applications
  293. In Vitro Growth of Thymic Tumor Cell Lines fromXenopus
  294. An abnormal concentration of cases of Rendu-Osler disease in the Valserine valley of the French Jura: a genealogical and demographic study
  295. Variability in the pharmacokinetics of epirubicin: a population analysis
  296. AXenopus laeviscreatine kinase isozyme (CK-III/III) expressed preferentially in larval striated muscle: cDNA sequence, developmental expression and subcellular immunolocalization
  297. Limited sampling models for doxorubicin pharmacokinetics.
  298. Differential expression of creatine kinase isozymes during development of Xenopus laevis: An unusual heterodimeric isozyme appears at metamorphosis
  299. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients
  300. Shifts in interleukin-4 and interferon-γ production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis
  301. Fraser syndrome with renal agenesis in two consanguineous Turkish families
  302. Influence of trimetazidine on deleterious effect of oxygen radical species in post-ischemic acute renal failure in the rat
  303. Cellular pharmacology of 4'-iodo-4'-deoxydoxorubicin
  304. Development of Mechanisms of Protection Against Oxidative Stress in Doxorubicin-Resistant Rat Tumoral Cells in Culture
  305. Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug
  306. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture
  307. Assessment of the experimental model of transplanted C6 glioblastoma in wistar rats
  308. Age‐related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population
  309. Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients
  310. DUCHENNE MUSCULAR DYSTROPHY: NEONATAL SCREENING AND PRENATAL DIAGNOSIS
  311. Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells
  312. Alteration of ganglioside composition and metabolism in doxorubicin-resistant rat tumoral cells
  313. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes
  314. Purification and characterization of cytoplasmic creatine kinase isozymes ofXenopus laevis
  315. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients
  316. The reversal of doxorubicin resistance by verapamil is not due to an effect on calcium channels
  317. Purification and characterization of a casein‐kinase‐II‐type enzyme from Xenopus laevis ovary
  318. Free fatty acid uptake is increased in doxorubicin-resistant glioblastoma cells
  319. Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated prefused rat liver
  320. Pharmacokinetics of doxorubicin in sarcoma patients
  321. Continuous Infusion or Intravenous Bolus: What Is the Rationale for Doxorubicin Administration?
  322. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients
  323. Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture
  324. Hepatic metabolism of doxorubicin in mice and rats
  325. Fluorescence anisotropy of kidney lipids and membranes of a hibernating mammal
  326. Cellular Pharmacology of Doxorubicin in Sensitive and Resistant Rat Glioblastoma Cells in Culture
  327. Evaluation of Drug Therapy and Teratogenic Risk in a Rhone-Alpes District Population of Pregnant Epileptic Women
  328. Tentative dose-monitoring of doxorubicin in lymphoma patients
  329. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients
  330. Incorporation and turnover of phospholipid precursors in normal and tumoral glial cells in culture
  331. Fluorescence polarization study of lipids and membranes prepared from brain hemispheres of a hibernating mammal
  332. Cellular Pharmacokinetics of Doxorubicin in Cultured Mouse Sarcoma Cells Originating from Autochthonous Tumors
  333. Incorporation and metabolism of exogenous fatty acids by cultured normal and tumoral glial cells
  334. Early-phase pharmacokinetics of doxorubicin in non-hodgkin lymphoma patients
  335. Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells
  336. Pharmacokinetics of adriamycin in patients with breast cancer: Correlation between pharmacokinetic parameters and clinical short-term response
  337. Changes in lipid composition of the brain cellular membranes of an hibernating mammal during its circannual rhythm
  338. Rectocolic familial polyposis; a study of 32 cases
  339. Sanfilippo A syndrome (Mucopolysaccharidosis III A): a neurochemical study
  340. Phospholipid acyl group composition in normal and tumoral nerve cells in culture
  341. Uptake of l‐Glutamate and Taurine in Neuroblastoma Cells with Altered Fatty Acid Composition of Membrane Phospholipids
  342. Extraction of Anthracyclines from Biological Fluids for HPLC Evaluation
  343. Membrane lipids in bromodeoxyuridine‐differentiated astroglial cells in culture
  344. Dynamics of Phospholipids in Cultured Cells of Neural Origin
  345. SYSTEMATIC NEONATAL SCREENING FOR DUCHENNE MUSCULAR DYSTROPHY
  346. UTILIZATION OF POLYUNSATURATED FATTY ACID SUPPLEMENTS BY CULTURED NEUROBLASTOMA CELLS1
  347. Confirmation of the assignment of the human <i>SOD<sub>S</sub> </i>gene to chromosome 21q22
  348. Polar head groups manipulation of phospholipids in cultured neuroblastoma cells
  349. Gangliosides of Active and Inactive Neuroblastoma Clones
  350. Thin-layer chromatography of gangliosides
  351. Essential fatty acid metabolism in cultured astroblasts
  352. IS VARICELLA VIRUS TERATOGENIC?
  353. NEUTRAL LIPIDS AND PHOSPHOLIPIDS FROM CULTURED ASTROBLASTS
  354. Changes in Sugar Composition of Membrane-Bound Glycoproteins during Postnatal Development of Rat Cerebellum
  355. Changes of Ganglioside Pattern during Postnatal Development of Rat Cerebellum
  356. Quantitation of neutral glycolipids by thin-layer chromatography on precoated plates
  357. Gangliosides of glial cells: A comparative study of normal astroblasts in tissue culture and glial cells isolated on sucrose‐ficoll gradients
  358. Pericentric inversion, inv(10), in a mother and aneusomy by recombination, inv(10),rec(10), in her son